interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Capivasertib

Generic competition · all medicines · read 12 November 2026

Is there a generic of Capivasertib, and who makes it?

Capivasertib appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Capivasertib1 dosage-form group in the Orange Book
0generic makers listed
  1. Capivasertib appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Truqap. No generic is listed as marketed.

202020252030203501brand 2023data datePatent 11760760 listed to expire 10 October 2028Patent 10654855 listed to expire 10 October 2028Patent 12252495 listed to expire 10 October 2028Patent 11236095 listed to expire 10 October 2028Patent 9492453 listed to expire 10 October 2028Patent 10059714 listed to expire 10 October 2028Patent 8101623 listed to expire 10 March 2030Patent 10039766 listed to expire 16 April 2033Patent 9487525 listed to expire 16 April 2033Exclusivity NCE to 16 November 2028Exclusivity I-991 to 12 June 2029
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 16 November 2028Exclusivity NCE Truqap
  • 12 June 2029Exclusivity I-991 Truqap
  • 10 October 2028Patent 11760760
  • 10 October 2028Patent 10654855
  • 10 October 2028Patent 12252495
  • 10 October 2028Patent 11236095
  • 10 October 2028Patent 9492453
  • 10 October 2028Patent 10059714 drug substance
  • 10 March 2030Patent 8101623 drug substance
  • 16 April 2033Patent 10039766

1 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.